Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abivax Sa ADR (ABVX)

Abivax Sa ADR (ABVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,396,022
  • Shares Outstanding, K 78,444
  • Annual Sales, $ 0 K
  • Annual Income, $ -190,710 K
  • EBIT $ -197 M
  • EBITDA $ -196 M
  • 60-Month Beta 0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.32

Options Overview Details

View History
  • Implied Volatility 78.62% (+1.52%)
  • Historical Volatility 55.39%
  • IV Percentile 38%
  • IV Rank 29.33%
  • IV High 158.74% on 12/11/25
  • IV Low 45.36% on 10/22/25
  • Expected Move (DTE 2) 4.59 (3.85%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 1,912
  • Volume Avg (30-Day) 4,962
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 73,317
  • Open Int (30-Day) 82,072
  • Expected Range 114.59 to 123.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.24
  • Number of Estimates 1
  • High Estimate -2.24
  • Low Estimate -2.24
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.42 +10.95%
on 02/02/26
130.13 -8.41%
on 01/15/26
+4.78 (+4.18%)
since 01/09/26
3-Month
100.50 +18.59%
on 11/13/25
148.83 -19.92%
on 12/24/25
+13.06 (+12.31%)
since 11/10/25
52-Week
4.77 +2,398.53%
on 04/09/25
148.83 -19.92%
on 12/24/25
+112.55 (+1,697.59%)
since 02/10/25

Most Recent Stories

More News
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst

In a report released on October 6, Thomas Smith from Leerink Partners reiterated a Buy rating on Abivax SA Sponsored ADR. The company’s shares closed yesterday at $87.01.Elevate Your Investing Strategy:...

ABVX : 119.18 (-0.50%)
Kepler Capital Sticks to Their Buy Rating for Abivax SA (0RA9)

Kepler Capital analyst Justine Telliez maintained a Buy rating on Abivax SA on October 6 and set a price target of €70.00. The company’s shares closed yesterday at €73.50.Elevate Your Investing Strategy:...

ABVX : 119.18 (-0.50%)
Why This French Biotech Stock Just Soared 586% in One Day

Shares of Abivax SA (NASDAQ: ABVX) went parabolic on Wednesday, skyrocketing 586% to close at $68.60 after the French biotech firm announced overwhelmingly positive Phase 3 data for its lead drug candidate,...

NDAQ : 82.51 (-4.39%)
PTN : 16.86 (+1.26%)
ABVX : 119.18 (-0.50%)
PTNT : 8.5300 (-15.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax SA is based in PARIS, FRANCE.

See More

Key Turning Points

3rd Resistance Point 125.43
2nd Resistance Point 123.99
1st Resistance Point 121.58
Last Price 119.18
1st Support Level 117.73
2nd Support Level 116.29
3rd Support Level 113.88

See More

52-Week High 148.83
Last Price 119.18
Fibonacci 61.8% 93.80
Fibonacci 50% 76.80
Fibonacci 38.2% 59.80
52-Week Low 4.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar